Skip to main content

NANO-MONITOREO DE LA EFICACIA DE UN TRATAMIENTO INMUNOTERAPEUTICO CONTRA EL CANCER: LA PLATAFORMA DE BIOENSAYO ELECTROFORÉTICO LATERAL

AC21_2/00044

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Programación Conjunta Internacional
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO CATALAN DE NANOCIENCIA Y NANOTECNOLOGIA
Execution centre FUNDACION INSTITUTO CATALAN DE NANOCIENCIA Y NANOTECNOLOGIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Toward Next Generation Lateral Flow Assays, Integration of Nanomaterials

  • Sena-Torralba, Amadeo|||0000-0003-1340-1383
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Parolo, Claudio|||0000-0001-9481-4408
  • Piper, Andrew|||0000-0002-1208-8009
  • Merkoçi, Arben|||0000-0003-2486-8085
Lateral flow assays (LFAs) are currently the most used point-of-care sensors for both diagnostic (e.g., pregnancy test, COVID-19 monitoring) and environmental (e.g., pesticides and bacterial monitoring) applications. Although the core of LFA technology was developed several decades ago, in recent years the integration of novel nanomaterials as signal transducers or receptor immobilization platforms has brought improved analytical capabilities. In this Review, we present how nanomaterial-based LFAs can address the inherent challenges of point-of-care (PoC) diagnostics such as sensitivity enhancement, lowering of detection limits, multiplexing, and quantification of analytes in complex samples. Specifically, we highlight the strategies that can synergistically solve the limitations of current LFAs and that have proven commercial feasibility. Finally, we discuss the barriers toward commercialization and the next generation of LFAs.